

Evidence dossier - Sarah Ketterer - Causeway Capital Management

GetCoattail manager profile: <https://getcoattail.com/manager/sarah-ketterer-causeway-capital-management> | CIK 0001165797 | Rank #55 of 149 tracked managers by reported 13F value.

Background: Founded: 2001 | HQ: Los Angeles, CA | Style: Global and international value equity, combining fundamental and quantitative research | Key person: Sarah Ketterer

Background

source:

<https://www.businesswire.com/news/home/20260702306651/en/Causeway-Capital-Management-Celebrates-25-Years-of-Disciplined-Global-Investing>

1. Latest filing snapshot (as reported)

Period end: 2026-06-30 Filed: 2026-08-13 Reported total value: \$9.2B Positions: 122 Top-10 concentration: 65.3% of reported value.

Ticker	Company	Weight	Reported value
AZN	Astrazeneca Plc	18.97%	\$1.8B
CCL	Carnival Corp Ltd	12.74%	\$1.2B
DB	Deutsche Bank Ag	10.77%	\$994M
SW	Smurfit Westrock Plc	7.53%	\$696M
CP	Canadian Pacific Kansas City Ltd	6.30%	\$582M
TSM	Taiwan Semiconductor Manufacturing Co Ltd	2.75%	\$254M
ALK	Alaska Air Group Inc	1.80%	\$166M
CARR	Carrier Global Corp	1.73%	\$160M
LYV	Live Nation Entertainment Inc	1.40%	\$129M
MRK	Merck & Co Inc	1.33%	\$123M

2. Hypothetical 13F-clone results

Window: 2016-11-14 to 2026-10-02 (40 filings). Cumulative: +225.3% CAGR: +12.68% SPY same window: cumulative +316.1%, CAGR +15.52%. Trailing CAGR - 10Y: n/a, 5Y: +11.41%, 3Y: +19.62%, 1Y: +9.79%. Max drawdown (month-end, approximate): -30.3%.

Method (summary): For each Form 13F filing in the history table, the clone takes the positions and weights exactly as disclosed (reported values at the period end). From the filing date until the next filing date, each position earns the return of its dividend-adjusted closing price (Yahoo Finance daily bars; split- and dividend-adjusted). At each new filing the clone rebalances to the newly disclosed weights. Positions that cannot be priced (non-U.S. listings, some recent IPOs and delisted names) are excluded from both the weights and the returns, and the covered share of reported value is stated in this dossier. The benchmark is SPY on the same dividend-adjusted basis over the identical window. Month-end values are used for drawdown and trailing-window statistics and are approximate.

3. Filing history - every clone input

Each row is one SEC Form 13F filing used by the clone. Accession numbers link to the filing index at sec.gov: <https://www.sec.gov/Archives/edgar/data/<CIK>/<accession without dashes>/<accession>-index.htm>

Quarter	Accession no.	Filed	CUSIPs
2016Q3	0001140361-16-086041	2016-11-14	82
2016Q4	0001140361-17-006736	2017-02-14	85
2017Q1	0001140361-17-025181	2017-06-15	81
2017Q2	0001140361-17-031599	2017-08-14	83
2017Q3	0001140361-17-042509	2017-11-14	88

2017Q4	0001140361-18-007644	2018-02-14	92
2018Q1	0001140361-18-023564	2018-05-15	88
2018Q2	0001567619-18-000771	2018-08-14	93
2018Q3	0001567619-18-006033	2018-11-14	88
2018Q4	0001567619-19-003953	2019-02-14	90
2019Q1	0001567619-19-010980	2019-05-15	89
2019Q2	0001567619-19-016702	2019-08-14	87
2019Q3	0001567619-19-021346	2019-11-14	86
2019Q4	0001567619-20-003630	2020-02-14	87
2020Q1	0001567619-20-010263	2020-05-15	85
2020Q2	0001567619-20-015209	2020-08-14	79
2020Q3	0001567619-20-019363	2020-11-13	79
2020Q4	0001567619-21-003391	2021-02-12	80
2021Q1	0001567619-21-010055	2021-05-14	82
2021Q2	0001567619-21-015404	2021-08-13	78
2021Q3	0001567619-21-019892	2021-11-12	81
2021Q4	0001567619-22-003403	2022-02-11	82
2022Q1	0001567619-22-010488	2022-05-13	75
2022Q2	0001567619-22-016013	2022-08-15	80
2022Q3	0001567619-22-019807	2022-11-14	81
2022Q4	0001567619-23-002449	2023-02-13	83
2023Q1	0001567619-23-006055	2023-05-12	81
2023Q2	0000894579-23-000230	2023-08-11	81
2023Q3	0000943663-23-000182	2023-11-13	89
2023Q4	0000943663-24-000054	2024-02-14	89
2024Q1	0000943663-24-000131	2024-05-15	89
2024Q2	0000943663-24-000204	2024-08-13	90
2024Q3	0000943663-24-000262	2024-11-13	97
2024Q4	0000943663-25-000047	2025-02-13	107
2025Q1	0000943663-25-000132	2025-05-14	90
2025Q2	0000943663-25-000224	2025-08-13	99
2025Q3	0000945621-25-001081	2025-11-13	105
2025Q4	0000945621-26-000303	2026-02-13	108
2026Q1	0000945621-26-000700	2026-05-14	107
2026Q2	0000945621-26-001052	2026-08-13	122

4. Coverage and adjustments

Price coverage at the latest filing: 52.4% of reported value is covered by our price history and included in the clone; the rest is excluded (mostly non-U.S. listings, recent IPOs, delisted names).

5. Disclaimer

This document and the associated web profile present a hypothetical replication ("13F clone") of the long U.S. equity positions disclosed on Form 13F. It is not the named fund's actual investment return: Form 13F excludes short positions, bonds, cash, non-U.S. listings, private holdings, leverage and fees, and positions are only observable quarterly, with a filing lag of up to 45 days. Nothing here is investment advice or a recommendation. Past hypothetical performance does not guarantee future results.